Liu Jiamin, He Ling, Jiang Wenjing, Xie Ping
Department of Gynecology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Front Pharmacol. 2024 Sep 25;15:1426988. doi: 10.3389/fphar.2024.1426988. eCollection 2024.
CDK7 has been demonstrated to play a crucial role in the initiation and progression of malignancy. Therefore, targeting CDK7, which regulates the transcription process, has emerged as a new promising approach for treating cancer. Research on CDK7 inhibitors has significantly increased over the past 2 decades, with almost 600 related papers in the Web of Science Core Collection database. To effectively identify future research hotspots and potential future directions, it is crucial to systematically review and visually present the research on this topic from a comprehensive viewpoint, ensuring scientific reliability.
This study performed bibliometric analysis via CiteSpace and VOSviewer scientometrics analysis software to examine data on the publication of articles on CDK7 inhibitors over the past 2 decades; the data included country of publication, author names, institution names, scientific categories, cited journals, and keywords related to the field of CDK7 inhibitors.
This bibliometric analysis included 426 publications from 41 different nations, referencing a total of 15,892 sources. Research associated with CDK7 inhibitors has rapidly expanded since 2016, and the US and China are the two countries with the highest publication output among the countries and institutes that produce literature on CDK7 inhibitors. Furthermore, the US is the country that most frequently engages in international cooperation. The evolution of keywords identifying antitumor strategies related to CDK7-mediated cellular transcription processes has been the research focus in recent years.
In this study, we identified research efforts and their evolving patterns and predicted advances in the CDK7 inhibitor field. The knowledge structure of CDK7 inhibitors encompasses pharmacological mechanisms, therapeutic targets, and cancer treatment strategies. The primary objectives of contemporary research are to discover the processes underlying cancer progression, identify specific signaling pathways, and develop effective clinical medicines.
细胞周期蛋白依赖性激酶7（CDK7）已被证明在恶性肿瘤的发生和发展中起关键作用。因此，靶向调控转录过程的CDK7已成为一种新的、有前景的癌症治疗方法。在过去20年中，关于CDK7抑制剂的研究显著增加，科学网核心合集数据库中有近600篇相关论文。为了有效识别未来的研究热点和潜在方向，从全面的角度系统回顾并直观呈现该主题的研究至关重要，以确保科学可靠性。
本研究通过CiteSpace和VOSviewer科学计量分析软件进行文献计量分析，以检验过去20年中关于CDK7抑制剂的文章发表数据；数据包括发表国家、作者姓名、机构名称、科学类别、被引期刊以及与CDK7抑制剂领域相关的关键词。
这项文献计量分析包括来自41个不同国家的426篇出版物，共引用了15,892个来源。自2016年以来，与CDK7抑制剂相关的研究迅速扩展，美国和中国是在产生关于CDK7抑制剂文献的国家和机构中发表量最高的两个国家。此外，美国是最常参与国际合作的国家。近年来，识别与CDK7介导的细胞转录过程相关的抗肿瘤策略的关键词演变一直是研究重点。
在本研究中，我们识别了研究工作及其演变模式，并预测了CDK7抑制剂领域的进展。CDK7抑制剂的知识结构包括药理机制、治疗靶点和癌症治疗策略。当代研究的主要目标是发现癌症进展的潜在过程、识别特定信号通路并开发有效的临床药物。
